Gerinnungsmanagement einschließlich Umkehrung der Antikoagulation

Reversal of antithrombotic agents. (öffnet neues Fenster)

Bauer KA.

Quelle‎: Am J Hematol 2012;87 Suppl 1:S119-26.

Indiziert‎: PubMed 22460529

DOI‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (öffnet neues Fenster)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (öffnet neues Fenster)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Quelle‎: J Thromb Haemost 2015;13(10):1790-8.

Indiziert‎: PubMed 26270886

DOI‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (öffnet neues Fenster)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (öffnet neues Fenster)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Quelle‎: N Engl J Med 2019;380(14):1326-35.

Indiziert‎: PubMed 30730782

DOI‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (öffnet neues Fenster)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (öffnet neues Fenster)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Quelle‎: N Engl J Med 2016;375(12):1131-41.

Indiziert‎: PubMed 27573206

DOI‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (öffnet neues Fenster)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (öffnet neues Fenster)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Quelle‎: Circulation 2011;124(14):1573-9.

Indiziert‎: PubMed 21900088

DOI‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (öffnet neues Fenster)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (öffnet neues Fenster)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Quelle‎: Lancet 2015;385(9982):2077-87.

Indiziert‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (öffnet neues Fenster)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (öffnet neues Fenster)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Quelle‎: J Trauma Acute Care Surg 2013;75(3):475-86.

Indiziert‎: PubMed 24089118

DOI‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (öffnet neues Fenster)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (öffnet neues Fenster)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Quelle‎: Am J Hematol 2012;87 Suppl 1:S141-5.

Indiziert‎: PubMed 22473649

DOI‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (öffnet neues Fenster)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (öffnet neues Fenster)

Levi M, Eerenberg E, Kamphuisen PW.

Quelle‎: J Thromb Haemost 2011;9(9):1705-12.

Indiziert‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (öffnet neues Fenster)

Emergency reversal of warfarin anticoagulation. (öffnet neues Fenster)

Lin Y, Callum J.

Quelle‎: CMAJ 2010;182(18):2004.

Indiziert‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (öffnet neues Fenster)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (öffnet neues Fenster)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Quelle‎: Thromb Haemost 2012;108(2):217-24.

Indiziert‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (öffnet neues Fenster)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (öffnet neues Fenster)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Quelle‎: J Thromb Haemost 2008;6(4):622-31.

Indiziert‎: PubMed 18208533

DOI‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (öffnet neues Fenster)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (öffnet neues Fenster)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Quelle‎: Blood Adv 2019;3(2):158-67.

Indiziert‎: PubMed 30658963

DOI‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (öffnet neues Fenster)

Idarucizumab for dabigatran reversal. (öffnet neues Fenster)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Quelle‎: N Engl J Med 2015;373(6):511-20.

Indiziert‎: PubMed 26095746

DOI‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (öffnet neues Fenster)

Idarucizumab for dabigatran reversal - full cohort analysis. (öffnet neues Fenster)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Quelle‎: N Engl J Med 2017;377(5):431-41.

Indiziert‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (öffnet neues Fenster)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (öffnet neues Fenster)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Quelle‎: Blood 2003;102(13):4594-9.

Indiziert‎: PubMed 12920042

DOI‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (öffnet neues Fenster)

Role of agents for reversing the effects of target-specific oral anticoagulants. (öffnet neues Fenster)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Quelle‎: Am J Health Syst Pharm 2017;74(2):54-61.

Indiziert‎: PubMed 27895055

DOI‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (öffnet neues Fenster)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (öffnet neues Fenster)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Quelle‎: Anesth Analg 2011;113(4):703-10.

Indiziert‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (öffnet neues Fenster)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (öffnet neues Fenster)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Quelle‎: J Am Coll Cardiol 2017;70(24):3042-67.

Indiziert‎: PubMed 29203195

DOI‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (öffnet neues Fenster)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (öffnet neues Fenster)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Quelle‎: World Neurosurg 2014;81(1):110-5.

Indiziert‎: PubMed 23220122

DOI‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (öffnet neues Fenster)

Reversal of warfarin-induced hemorrhage in the emergency department. (öffnet neues Fenster)

Zareh M, Davis A, Henderson S.

Quelle‎: West J Emerg Med 2011;12(4):386-92.

Indiziert‎: PubMed 22224125

DOI‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (öffnet neues Fenster)

INTENSIVMEDIZIN

Gerinnungsmanagement einschließlich Umkehrung der Antikoagulation

Deutsch

Gerinnungsmanagement einschließlich Umkehrung der Antikoagulation

https://assetsnffrgf-a.akamaihd.net/assets/ct/e781f8601f/images/syn_placeholder_sqr.png

Gerinnungsmanagement einschließlich Umkehrung der Antikoagulation

Reversal of antithrombotic agents. (öffnet neues Fenster)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (öffnet neues Fenster)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (öffnet neues Fenster)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (öffnet neues Fenster)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (öffnet neues Fenster)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (öffnet neues Fenster)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (öffnet neues Fenster)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (öffnet neues Fenster)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (öffnet neues Fenster)

Emergency reversal of warfarin anticoagulation. (öffnet neues Fenster)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (öffnet neues Fenster)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (öffnet neues Fenster)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (öffnet neues Fenster)

Idarucizumab for dabigatran reversal. (öffnet neues Fenster)

Idarucizumab for dabigatran reversal - full cohort analysis. (öffnet neues Fenster)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (öffnet neues Fenster)

Role of agents for reversing the effects of target-specific oral anticoagulants. (öffnet neues Fenster)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (öffnet neues Fenster)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (öffnet neues Fenster)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (öffnet neues Fenster)

Reversal of warfarin-induced hemorrhage in the emergency department. (öffnet neues Fenster)

Ansprechpartner des Krankenhaus-Verbindungskomitees vor Ort

Informationen zum Herunterladen

Videos

Gerinnungsmanagement einschließlich Umkehrung der Antikoagulation

Wähle deine Sprache aus

Teilen